These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21344470)

  • 1. Flexible design clinical trial methodology in regulatory applications.
    Hung HM; Wang SJ; O'Neill R
    Stat Med; 2011 Jun; 30(13):1519-27. PubMed ID: 21344470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Issues in designing flexible trials.
    Posch M; Bauer P; Brannath W
    Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reassessment of trial perspectives from interim data--a critical view.
    Bauer P; Koenig F
    Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The advantages and disadvantages of adaptive designs for clinical trials.
    Bauer P; Brannath W
    Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing face of clinical trials.
    Kitler ME
    J Hypertens Suppl; 1988 Nov; 6(1):S73-80. PubMed ID: 3063796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive design in clinical research: issues, opportunities, and recommendations.
    Chang M; Chow SC; Pong A
    J Biopharm Stat; 2006 May; 16(3):299-309; discussion 311-2. PubMed ID: 16724486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressors and the search for the optimal trial design.
    Maharaj R
    Contemp Clin Trials; 2011 Nov; 32(6):924-30. PubMed ID: 21807122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of draft FDA adaptive design guidance.
    Cook T; DeMets DL
    J Biopharm Stat; 2010 Nov; 20(6):1132-42. PubMed ID: 21058109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible design of two-stage adaptive procedures for phase III clinical trials.
    Koyama T
    Contemp Clin Trials; 2007 Jul; 28(4):500-13. PubMed ID: 17307399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection and bias--two hostile brothers.
    Bauer P; Koenig F; Brannath W; Posch M
    Stat Med; 2010 Jan; 29(1):1-13. PubMed ID: 19844944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval.
    Liu GF; Zhu GR; Cui L
    Stat Med; 2008 Feb; 27(4):584-96. PubMed ID: 17634972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.
    Boessen R; van der Baan F; Groenwold R; Egberts A; Klungel O; Grobbee D; Knol M; Roes K
    Pharm Stat; 2013; 12(6):366-74. PubMed ID: 24214896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
    Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
    J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials.
    Wang SJ; James Hung HM; O'Neill RT
    Biom J; 2010 Dec; 52(6):798-810. PubMed ID: 21154897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.